Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective
Jessica Elliott, Rachel Koldej, Amit Khot, David Ritchie (2025). Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective. , DOI: https://doi.org/10.1007/978-1-0716-4430-0_1.
Article268 days agoCAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study
Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine S. Tam, Piers Blombery, David Westerman, David Ritchie, Huw Morgan, Nicholas Holzwart, Stephen Lade, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen Caldwell, Georgina L. Ryland, Javad Saghebi, Zahra Sabahi, Jing Xie, Rachel Koldej, Michael Dickinson (2023). CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study. , 143(8), DOI: https://doi.org/10.1182/blood.2023021306.
Article268 days agoTime-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with <i>TP53</i> Mutated and Btki-Refractory Disease: First Report of the Tarmac Study
Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine S. Tam, Piers Blombery, David Westerman, Stephen Lade, David Ritchie, Rachel Koldej, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen Caldwell, Georgina L. Ryland, Jing Xie, Huw Morgan, Michael Dickinson (2022). Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with <i>TP53</i> Mutated and Btki-Refractory Disease: First Report of the Tarmac Study. , 140(Supplement 1), DOI: https://doi.org/10.1182/blood-2022-160459.
Article268 days agoWho will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies
Jessica Elliott, David Ritchie, Rachel Koldej, Amit Khot (2026). Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies. , DOI: https://doi.org/10.1016/s2352-3026(26)00005-0.
Article5 days agoVenetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
Sasanka M. Handunnetti, Amit Khot, Piers Blombery, Kate Burbury, Philip A. Thompson, David Ritchie, Rodney J. Hicks, Glenda Burke, Rachel Koldej, Mathias Bressel, Juliana L Di Iulio, David Westerman, Stephen Lade, John F. Seymour, Constantine S. Tam, Mary Ann Anderson (2025). Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma. , 10(5), DOI: https://doi.org/10.1182/bloodadvances.2025016646.
Article5 days ago